Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Codiak BioSciences, Inc.CDAK · Entity 114958 | Chief Medical Officer | January 24, 2023 | January 26, 2023 |
| Prelude Therapeutics IncPRLD · Entity 5561 | Chief Medical Officer | October 05, 2021 | October 06, 2021 |
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Chief Medical Officer | November 15, 2024 | November 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Codiak BioSciences, Inc.
Report date January 24, 2023 · Filed January 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2033-01-23 | Direct | 190,000 |
Reported balance
After 2023-01-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-24 · Grant · Acquired 190,000 · Balance 190,000 F1: 25% of this option shall vest and become exercisable on January 24, 2024, with the remainder vesting in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on January 24, 2024, with the remainder vesting in 12 equal quarterly installments thereafter.
Prelude Therapeutics Inc
Report date October 05, 2021 · Filed October 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-10-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-10-05 · Exercise / conversion · Acquired 15,000 · Balance 15,000 Row 2 · 2021-10-05 · Sale · Disposed 5,908 · Balance 9,092 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Row 3 · 2021-10-05 · Sale · Disposed 7,803 · Balance 1,289 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.87 to $31.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Row 4 · 2021-10-05 · Sale · Disposed 1,289 · Balance 0 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2029-07-17 | Direct | 137,610 |
Reported balance
After 2021-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-10-05 · Exercise / conversion · Disposed 15,000 · Balance 137,610 F5: The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.87 to $31.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F5: The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
RECURSION PHARMACEUTICALS, INC.
Report date November 15, 2024 · Filed November 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 225,429 |
Reported balance
After 2024-11-15 transaction · row 1
1 source rowRow 1 · 2024-11-15 · Tax withholding · Disposed 4,187 · Balance 225,429 F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.09 · Expires 2034-02-09 | Direct | 99,537 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 99,537 F2: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2033-06-01 | Direct | 381,426 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 381,426 F3: This option vests as to one fourth (1/4th) of the shares subject to the option on June 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F3: This option vests as to one fourth (1/4th) of the shares subject to the option on June 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 19, 2021 Filed Apr 21, 2021 19:56 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-027874 · doc4.xml · derivative · entry 4 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,610 Underlying: Common Stock · 25,000 shares Expires 2029-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 19:56 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 4,000 | $31.27 | $125,076.80 |
DisclosureSEC source: 0001209191-21-027874 · doc4.xml · nonDerivative · entry 3 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.19 to $31.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 19:56 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 21,000 | $30.82 | $647,272.50 |
DisclosureSEC source: 0001209191-21-027874 · doc4.xml · nonDerivative · entry 2 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.19 to $31.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 19:56 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 25,000 | $1.89 | $47,250.00 |
DisclosureSEC source: 0001209191-21-027874 · doc4.xml · nonDerivative · entry 1 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 19:09 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,617 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-026872 · doc4.xml · derivative · entry 6 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,610 Underlying: Common Stock · 9,617 shares Expires 2029-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 19:09 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 3,549 | $39.56 | $140,392.76 |
DisclosureSEC source: 0001209191-21-026872 · doc4.xml · nonDerivative · entry 5 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.38 to $40.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 19:09 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 1,293 | $39.00 | $50,423.38 |
DisclosureSEC source: 0001209191-21-026872 · doc4.xml · nonDerivative · entry 4 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,549 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.38 to $39.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 19:09 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 1,501 | $37.83 | $56,780.28 |
DisclosureSEC source: 0001209191-21-026872 · doc4.xml · nonDerivative · entry 3 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,842 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.38 to $38.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 19:09 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 3,274 | $37.04 | $121,255.86 |
DisclosureSEC source: 0001209191-21-026872 · doc4.xml · nonDerivative · entry 2 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,343 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.37 to $37.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 08, 2021 Filed Apr 15, 2021 19:09 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 9,617 | $1.89 | $18,176.13 |
DisclosureSEC source: 0001209191-21-026872 · doc4.xml · nonDerivative · entry 1 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 17:50 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,383 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-21-026291 · doc4.xml · derivative · entry 4 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,227 Underlying: Common Stock · 15,383 shares Expires 2029-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 17:50 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 7,083 | $39.69 | $281,115.77 |
DisclosureSEC source: 0001209191-21-026291 · doc4.xml · nonDerivative · entry 3 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.30 to $40.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 17:50 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 8,300 | $39.03 | $323,907.50 |
DisclosureSEC source: 0001209191-21-026291 · doc4.xml · nonDerivative · entry 2 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,083 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.30 to $39.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 17:50 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 15,383 | $1.89 | $29,073.87 |
DisclosureSEC source: 0001209191-21-026291 · doc4.xml · nonDerivative · entry 1 Mauro David J · CIK 0001621172 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.